Brentuximab bedotin (BV; AdsetrisR, SGN-35) is an ADC comprising an anti-CD30 mAb conjugated by a protease cleavable linker to the potent anti-microtube agent, monomethyl auristatin E (MMAE), which was developed and approved for relapsed or refractory Hodgkin’s lymphoma (HL), cutaneous T cell lymphoma (CTCL) and anaplastic large T cell lymphoma (ALCL) [60,61,62]. Here, TNFRSF8 is linked to Hodgkins lymphoma.